Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
ABCB1 genotyping for epileptic patients is not warranted.
|
20491876 |
2010 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.
|
26122019 |
2016 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
C3435T polymorphism of MDR1 gene was analysed by the high resolution melting technique in a group of patients with drug-resistant (n = 106) and drug-responsive epilepsy (n = 67), as well as in non-epileptic children (n = 98) hospitalised at the Department of Neurology, Polish Mother's Memorial Hospital in Lodz.
|
27391700 |
2016 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Conflicting reports suggest a possible association between variants of the MDR1 gene and medical intractability in epilepsy.
|
15679503 |
2005 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We included all published studies until September 2007, in which patients with responsive and unresponsive seizure disorders underwent genotyping for ABCB1 C3435T.
|
19178561 |
2009 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Further analysis using a logistic regression model revealed that only 2677G>T and 3435C>T in the ABCB1 gene and their interaction term were associated with drug-resistant epilepsy after adjustment for etiology and epilepsy classification.
|
17924830 |
2007 |
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
We aimed to determine the effect of the ABCB1 gene on epilepsy drug response, using a unique large cohort of epilepsy patients with prospectively measured seizure and drug response outcomes.
|
16857572 |
2006 |
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
ATP-binding cassette sub-family B member 1 (ABCB1) is a membrane-associated protein that acts as an efflux transporter for many substrates, including chemotherapeutic agents, anti-epilepsy medicine, antibiotics and drugs for PD.
|
24572589 |
2014 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our finding disproves a general association between ABCB1 polymorphisms and drug response in epilepsy patients.
|
20417680 |
2010 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The study failed to corroborate association between polymorphism CYP3A5*3 and C3435T polymorphism in MDR1 gene and pharmacoresistant epilepsy.
|
23984379 |
2013 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We studied the association between C3435T and G2677T/A ABCB1 gene polymorphisms and drug resistance in Iranian epilepsy patients.
|
21636342 |
2011 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Significance of MDR1 gene polymorphism C3435T in predicting drug response in epilepsy.
|
24300029 |
2014 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The association between the non-synonymous polymorphism G2677T/A in the coding region of the ABCB1 gene, and the risk of resistance to anti-epileptic drugs (AEDs) in epilepsy remains controversial.
|
26220385 |
2015 |
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
ABCB1 3435 was genotyped in 315 patients with epilepsy, classified as drug-resistant in 200 and drug-responsive in 115, and 200 control subjects without epilepsy.
|
12686700 |
2003 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Multidrug-resistant genotype (ABCB1) and seizure recurrence in newly treated epilepsy: data from international pharmacogenetic cohorts.
|
19453704 |
2009 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The analysis showed that there were significantly more cases with the MDR1 3435 CC genotype in the group with drug-resistant epilepsy than in the group with drug-responsive epilepsy [odds ratio (OR)=1.50, 95% confidence interval (CI)=1.09-2.06, P=0.01].
|
24953225 |
2014 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
ABCB1 gene C3435T polymorphism and drug resistance in epilepsy: evidence based on 8,604 subjects.
|
25799371 |
2015 |
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study aimed to assess whether [<sup>11</sup>C]flumazenil is a P-glycoprotein substrate in humans and to what extent increased P-glycoprotein function in epilepsy may confound interpretation of clinical [<sup>11</sup>C]flumazenil studies used to assess gamma-aminobutyric acid A receptors.
|
26661244 |
2017 |
Epilepsy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The P-gp encoded by the ABCB1 and ABCC2 genes are expressed in drug resistant patients with epilepsy.
|
23717663 |
2013 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Previous studies reported the associations between the ATP-binding cassette sub-family B member 1 (ABCB1, also known as MDR1) polymorphisms and their haplotypes with risk of response to antiepileptic drugs in epilepsy, however, the results were inconclusive.
|
25816099 |
2015 |
Epilepsy
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Further, for NF-κB p65, MDR1, P-gp and apoptosis-associated protein levels detection, miR-542-3p mimic showed a suppressive effect on these KA-induced protein levels, whereas TLR4 overexpression ameliorated the miR-542-3p-induced these protein levels in KA-treated epilepsy rats.
|
31702493 |
2019 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Here, we performed the first haplotype meta-analysis to examine the association of haplotypes of ABCB1 common variants with the response to treatment in epilepsy.
|
21391884 |
2011 |
Epilepsy
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
rs776746 and rs15524 in the CYP3A5 gene tend to affect CBZ metabolism, and rs2032582, rs10234411 in the ABCB1 gene may contribute to inter-individual variation in CBZ and in CBZ-E transport among patients with epilepsy using CBZ in combination with PHT or PB.
|
26421491 |
2015 |
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Indeed, many genes, including genes encoding drug transporters (ABCB1), drug targets (SCN1A), drug-metabolizing enzymes (CYP2C9, CYP2C19), and human leucocyte antigen (HLA) proteins, may regulate the mechanisms of drug resistance in epilepsy.
|
29804481 |
2018 |
Epilepsy
|
0.600 |
Biomarker
|
disease |
BEFREE |
Selective inhibitors of the major efflux transporter P-glycoprotein are currently in clinical trials for reversing chemotherapy resistance in oncology and may soon be used to determine whether such inhibitors can prevent or reverse drug resistance in epilepsy.
|
16120487 |
2005 |